GALECTIN THERAPEUTICS INC
Canonical company identity and public leadership record.
- Source reported. 25 claims from 3 sources.
- Not claimed by the company.
- Eval: not assessed.
- CEO
- Joel Lewis
- Chair
- Not published
- Board
- 10 directorsAlpha calculation. Published seats
- Independence
- 7 of 10Alpha calculation
- Committees
- 5
- Evidence
- 3 sources25 published claims
- Open conflicts
- 0None open
Leadership
3 claims| Person | Role | Since | Status | Evidence |
|---|---|---|---|---|
| Jack W. Callicutt | Chief Financial Officer | Current | Source reportedE3 | |
| Joel Lewis | Chief Executive Officer and President | Current | Source reportedE4 | |
| Khurram Jamil, M.D. | Chief Medical Officer | Current | Source reportedE5 |
Board
10 claims| Director | Status | Since | Committees | Evidence |
|---|---|---|---|---|
| Benjamin S. Carson, Sr., M.D. | Not independent | None published | Source reportedE2 | |
| Elissa J. Schwartz, Ph.D. | Independent | None published | Source reportedE2 | |
| Gilbert F. Amelio, Ph.D. | Independent | None published | Source reportedE2 | |
| Harold H. Shlevin, Ph.D. | Independent | None published | Source reportedE2 | |
| Joel Lewis | Not independent | None published | Source reportedE2 | |
| Kary Eldred | Independent | Audit | Source reportedE2 | |
| Kevin D. Freeman | Independent | Audit; Audit; Compensation; Nominating and Governance; Compensation; Nominating and Governance | Source reportedE2 | |
| Marc Rubin, M.D. | Independent | None published | Source reportedE2 | |
| Richard A. Zordani | Independent | Audit, chair; Audit · Chair | Source reportedE2 | |
| Richard E. Uihlein | Not independent | None published | Source reportedE2 |
Committees
8 claims| Committee | Chair | Members | Risks assigned | Evidence |
|---|---|---|---|---|
| Audit | Richard A. Zordani | Richard A. Zordani, Kary Eldred, Kevin D. Freeman | Not described in the published record | Source reportedE6 |
| Audit · Chair | Not published | Richard A. Zordani | Not described in the published record | |
| Audit; Compensation; Nominating and Governance | Not published | Kevin D. Freeman | Not described in the published record | |
| Compensation | Not published | Kevin D. Freeman | Not described in the published record | Source reportedE6 |
| Nominating and Governance | Not published | Kevin D. Freeman | Not described in the published record | Source reportedE6 |
| Fact | Stated value | Evidence |
|---|---|---|
| Committee appointment | Richard A. Zordani: chair, Audit | Source reportedE6 |
| Committee appointment | Kary Eldred: member, Audit | Source reportedE6 |
| Committee appointment | Kevin D. Freeman: member, Audit | Source reportedE6 |
| Committee appointment | Kevin D. Freeman: member, Compensation | Source reportedE6 |
| Committee appointment | Kevin D. Freeman: member, Nominating and Governance | Source reportedE6 |
Financial context
1 claim| Fact | Stated value | Evidence |
|---|---|---|
| Security listing | GALT (NASDAQ) | Source reportedE1 |
Other published claims
3 claims| Fact | Stated value | Evidence |
|---|---|---|
| Legal name | GALECTIN THERAPEUTICS INC | Source reportedE1 |
| Entity status | Public listing published | Source reportedE1 |
| Published fact | US | Source reportedE1 |
Evidence
6 evidence records| Ref | Source | Authority | Source date | Retrieved | Rights | Cited by |
|---|---|---|---|---|---|---|
| E1 | Alpha canonical company public projectionCanonical identity | Open web | Not recorded | Rights not recorded, link only | 4 claims | |
| E2 | GALECTIN THERAPEUTICS INC DEF 14A 2025-10-22SEC proxy | Authoritative, regulatory filing | Rights not recorded, link only | 10 claims | ||
| E3 | GALT 10-K executive officersSEC filing | Authoritative, regulatory filing | Rights not recorded, link only | 1 claim | ||
| E4 | GALT 10-K executive officersSEC filing | Authoritative, regulatory filing | Rights not recorded, link only | 1 claim | ||
| E5 | GALT 10-K executive officersSEC filing | Authoritative, regulatory filing | Rights not recorded, link only | 1 claim | ||
| E6 | Auditboard_seats. Board seats | Authoritative, regulatory filing | Not recorded | Not recorded | Rights not recorded, link only | 8 claims |
No evidence record is pinned or signed yet.
Not yet in this record
These parts of a company record have no published claims yet. That is a coverage state, not a finding about the company. 1 further claim is under review.
- Control and voting
- Governance
- Risk
- AI oversight
- Legal
- Compensation
Index memberships
No current membership is published in Alpha's tracked index universe.
This is not evidence that the company is absent from every market index.
As of 22 Nov 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Coverage states the record reports (12)
- Corporate structure
- Not reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- Ownership
- Not reviewed. Ownership and voting power determine who can influence the board.
- Financials
- Not reviewed. Governance-relevant financial context frames capital and audit decisions.
- Compensation
- Not reviewed. Pay design shows how incentives are governed.
- Governance
- Not reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governance
- Not reviewed. Meeting and vote records show shareholder dissent and support.
- Audit
- Not reviewed. Auditor, controls and restatements show assurance over reporting.
- Legal
- Not reviewed. Material legal and regulatory matters show enforcement exposure.
- Risk
- Not reviewed. Risk ownership links the board, committees, executives and controls.
- Cyber
- Not reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governance
- Not reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets external
- Not reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
Limits of this record (5)
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.
History
Version public-1Published .
- CFO role recorded. Jack W. Callicutt executive of GALECTIN THERAPEUTICS INC, effective 31 Mar 2026.Effective . Recorded .
- CEO role recorded. Joel Lewis executive of GALECTIN THERAPEUTICS INC, effective 31 Mar 2026.Effective . Recorded .
- Executive appointed. Khurram Jamil, M.D. executive of GALECTIN THERAPEUTICS INC, effective 31 Mar 2026.Effective . Recorded .
- Director appointed. Benjamin S. Carson, Sr., M.D. seat on GALECTIN THERAPEUTICS INC, effective 2023.Effective . Recorded .
- Director appointed. Elissa J. Schwartz, Ph.D. seat on GALECTIN THERAPEUTICS INC, effective 2020.Effective . Recorded .
- Director appointed. Richard A. Zordani seat on GALECTIN THERAPEUTICS INC, effective 2020.Effective . Recorded .
- Committee created. Audit · Chair committee of GALECTIN THERAPEUTICS INC, effective 2020.Effective . Recorded .
- Committee member added. Richard A. Zordani member of Audit · Chair, effective 2020.Effective . Recorded .
- Director appointed. Harold H. Shlevin, Ph.D. seat on GALECTIN THERAPEUTICS INC, effective 2019.Effective . Recorded .
- Director appointed. Kary Eldred seat on GALECTIN THERAPEUTICS INC, effective 2018.Effective . Recorded .
- Committee member added. Kary Eldred member of Audit, effective 2018.Effective . Recorded .
- Director appointed. Joel Lewis seat on GALECTIN THERAPEUTICS INC, effective 2017.Effective . Recorded .
- Director appointed. Richard E. Uihlein seat on GALECTIN THERAPEUTICS INC, effective 2017.Effective . Recorded .
- Director appointed. Kevin D. Freeman seat on GALECTIN THERAPEUTICS INC, effective 2011.Effective . Recorded .
- Director appointed. Marc Rubin, M.D. seat on GALECTIN THERAPEUTICS INC, effective 2011.Effective . Recorded .
- Committee created. Audit; Compensation; Nominating and Governance committee of GALECTIN THERAPEUTICS INC, effective 2011.Effective . Recorded .
- Committee member added. Kevin D. Freeman member of Audit; Compensation; Nominating and Governance, effective 2011.Effective . Recorded .
- Director appointed. Gilbert F. Amelio, Ph.D. seat on GALECTIN THERAPEUTICS INC, effective 2009.Effective . Recorded .
About this record
- Alpha ID
- alpha:company:8ec02b3b-19c0-427d-b1c8-424dbbe7ccad
- Version
- public-1:ro-d751713988987e9331980363e24189ce
- Identity
- Not claimed
- Evidence
- Source reported
- Evaluation
- Not assessed
- Monitoring
- Not monitored yet
- Authority
- Not published
- Freshness
- Current
- Integrity
- Not signed yet
- Basis
- Published company record built from public sources
- Never published
- Private company data: deployments, authority grants, TrustChecks, receipts, telemetry
The company can claim this record and correct or dispute any claim. Corrections are versioned and the original stays in history. A company's own statements are shown as its own and never replace the cited evidence.

